Learn the latest Small Cell Lung Cancer (SCLC) research. Hear from 14-year SCLC patient/advocate for the underdog, Montessa Lee, who took her anger and turned it into advocacy. Listen to lung cancer researcher Dr. Triparna Sen explain how DNA damage repair inhibitors are the “Achilles Heel” of SCLC tumors.
Montessa Lee: educator, lung cancer patient advocate, 14-year SCLC survivor
Dr. Triparna Sen, Memorial Sloan Kettering Cancer Center, New York
Cracking the Code of Small Cell Lung Cancer
Small cell lung cancer is the least common type of lung cancer, affecting only about 1 in 10 lung cancer patients. But SCLC spreads faster and is more lethal than non-small cell lung cancer. Research advances for small cell lung cancer have lagged behind those for non-small cell lung cancer, with no real progress in treatment for about 35 years.
However, in the last 5 – 6 years, researchers have gotten a much better understanding of lung cancer overall, and of small cell lung cancer in particular, with new treatments including immunotherapy and combination therapy being approved by the FDA. Listen to Dr. Sen explain more about this specific lung cancer and symptoms to know. She shares her hopes for future research to get a better understanding of drug resistance in treatment and find better ways to get patients in the right clinical trials.
Additional information on SCLC research
Research is making a difference in the treatment of lung cancer. Here is some additional information to get a better understanding about SCLC, including the latest small cell lung cancer (SCLC) research :